01—Abstract
Summary
Summary of the 8-K filed May 9, 2024. Cited figures are marked; the original filing is the authoritative source.
Guardant Health (GH) reported first quarter 2024 results on May 9, 2024, with total revenue of $168.5 milliona, up 31% year over year from $128.7 million.
Precision oncology revenue grew 38% to $156.2 millionb, driven by clinical test volume growth of 20% (46,900 tests), biopharma test volume growth of 37% (8,450 tests), and higher reimbursement, including an increase in the Medicare rate for Guardant360 LDT to $5,000 effective January 1, 2024. GAAP gross margin improved to 61% from 59%, and non-GAAP gross margin excluding screening reached 64%. Operating performance improved meaningfully: GAAP loss from operations narrowed to $99.7 million from $134.1 million, and free cash flow improved to $(37.2) million from $(82.0) million.
Management noted the first quarter of positive cash flow in the Therapy Selection business. The company raised its full-year 2024 revenue guidance (excluding screening) to $675c-$685 million, implying 20-21% growth, up from $655-$670 million. It also improved its free cash flow outlook to $(275)-$(285) million from $(320)-$(330) million and lowered its non-GAAP operating expense guidance to $720-$730 million.
Management highlighted an upcoming FDA Advisory Committee review of Shield IVD on May 23, 2024, with a product launch expected shortly after anticipated FDA approval in 2024. Net loss narrowed to $115.0 milliond ($0.94 per share) from $133.5 million ($1.30 per share), but the GAAP comparison was pressured by a $30.1 million unrealized loss on the company's marketable equity securities (investment in Lunit), partly offset by higher interest income.
Non-GAAP net loss was $56.4 million ($0.46 per share). The company held $1.1 billion in cash, cash equivalents and restricted cash at March 31, 2024, against $1.14 billion in convertible senior notes, and total stockholders' equity fell to $68.3 million from $158.7 million.
02—Key points
Key Highlights
- Total revenue rose 31% year over year to $168.5 million, with precision oncology revenue up 38% to $156.2 million
- Clinical test volume grew 20% to 46,900 tests and biopharma test volume grew 37% to 8,450 tests, supported by higher Guardant360 Medicare reimbursement ($5,000 effective January 1, 2024)
- Full-year 2024 revenue guidance (excluding screening) raised to $675-$685 million (20-21% growth) from $655-$670 million
- Free cash flow improved to $(37.2) million from $(82.0) million; full-year 2024 FCF guidance improved to $(275)-$(285) million from $(320)-$(330) million
- GAAP net loss narrowed to $115.0 million ($0.94 per share) from $133.5 million, though it included a $30.1 million unrealized loss on the Lunit equity investment
- Shield IVD FDA Advisory Committee review scheduled for May 23, 2024, with commercial launch planned shortly after expected 2024 FDA approval
- Cash, cash equivalents and restricted cash of $1.1 billion at March 31, 2024, versus $1.14 billion in convertible senior notes; stockholders' equity declined to $68.3 million
03—Questions
Frequently Asked Questions
What drove the 31% revenue growth in the first quarter of 2024?
Growth came from both volume and price. Clinical testing volume rose 20% and biopharma testing volume rose 37% year over year. Reimbursement also improved, reflecting the increase in the Medicare rate for Guardant360 LDT to $5,000 effective January 1, 2024, and higher commercial payer reimbursement.
Why did the company raise its 2024 revenue guidance?
The company raised its full-year 2024 revenue guidance (excluding screening) to $675-$685 million from $655-$670 million, citing strong first-quarter performance from volume growth and reimbursement tailwinds for Guardant360. The filing does not break down the specific contribution of each driver to the raised outlook.
Why does the GAAP net loss differ so much from the non-GAAP net loss?
GAAP net loss of $115.0 million includes stock-based compensation ($27.3 million), amortization of intangibles, contingent consideration, and a $30.1 million unrealized loss on marketable equity securities, mainly the Lunit investment. Non-GAAP net loss excludes these items and was $56.4 million, or $0.46 per share.
What are the key near-term catalysts for investors?
The most significant near-term catalyst is the FDA Advisory Committee review of Shield IVD on May 23, 2024. Management expects FDA approval in 2024 and a launch shortly afterward. Investors will also watch progress toward the company's improved free cash flow guidance of $(275)-$(285) million.
How is the company's balance sheet positioned?
Cash, cash equivalents and restricted cash totaled $1.1 billion at March 31, 2024, roughly in line with the $1.14 billion carrying value of convertible senior notes. Total stockholders' equity fell to $68.3 million from $158.7 million at year-end 2023, mainly because of the accumulated deficit, which grew by $115.0 million in the quarter.
04—Continue